Deutsche Bank AG Buys 96,329 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Deutsche Bank AG boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 539,269 shares of the biopharmaceutical company’s stock after acquiring an additional 96,329 shares during the quarter. Deutsche Bank AG owned 0.49% of Regeneron Pharmaceuticals worth $384,137,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in REGN. OFI Invest Asset Management bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $28,000. Rakuten Securities Inc. boosted its stake in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 15 shares during the last quarter. Avalon Trust Co purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $36,000. Crowley Wealth Management Inc. bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $36,000. Finally, Private Wealth Management Group LLC grew its stake in shares of Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 39 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 2.4 %

Regeneron Pharmaceuticals stock opened at $547.55 on Friday. The business’s 50-day simple moving average is $616.03 and its two-hundred day simple moving average is $699.76. The company has a market cap of $59.86 billion, a PE ratio of 14.30, a PEG ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $520.50 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion during the quarter, compared to analysts’ expectations of $3.40 billion. During the same period in the previous year, the company posted $9.55 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was down 3.7% compared to the same quarter last year. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be paid a $0.88 dividend. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.64%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.96%.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of analyst reports. Bank of America lowered their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a report on Thursday, April 17th. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 22nd. Bernstein Bank lowered their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Finally, Wells Fargo & Company reduced their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $700.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $892.60.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.